# Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

> **NCT03540303** · PHASE1 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Relapsed Non Hodgkin Lymphoma

## Interventions

- **DRUG:** CAR19 T cells carrying cytoplasmic activated PD-1

## Key facts

- **NCT ID:** NCT03540303
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-12
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2018-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540303, "Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03540303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*